Treatment of depression with cognitive impairment

Medvedev, V.; Ter-Israelyan, A Yu; Фролова, В. И.; Korovyakova, Elina; Gushanskaya, E V

doi:10.17116/jnevro20181182177-80

Cited by 8 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Целью открытого психофармакотерапевтического исследования, выполненного на кафедре психиатрии, психотерапии и психосоматической патологии факультета непрерывного медицинского образования Медицинского института ФГАОУ ВО «Российский университет дружбы народов», являлась оценка эффективности и переносимости монотерапии мелатонинергическим тимолептиком агомелатином (вальдоксан) [12][13][14][15][16][17][18][19][20] при депрессии с симптомами РПП.…”

unclassified

Depressions with eating disorders: clinical manifestations and therapy

Medvedev

Фролова

Gushanskaya

et al. 2020

RJTAO

Self Cite

View full text Add to dashboard Cite

Depression is a common comorbid diagnosis in patients with eating disorders (EDs). The development of pathogenetic therapy for depression with EDs is far from being completed.The objective of the psychopharmacotherapeutic study was to evaluate the efficacy and tolerability of melatonergic monotherapy with the antidepressant agomelatine (25–50 mg/day at night) for depressions with two ED variants: hyperphagic (n=32) and hypo- and aphagic (n=31) EDs.Patients and methods. The investigation enrolled patients of both sexes, aged 18 to 65 years. The investigators performed clinical psychopathological and experimental psychological studies, as well as psychometric examination using the 21-item Hamilton Depression Rating Scale (HDRS-21), the Clinical Global Impression (CGI), the Supplemental Hospital Offset Payment Program (SHOPP), the Dutch Eating Behavior Questionnaire (DEBQ), and statistical data processing.Results and discussion. There was a significant pronounced antidepressant effect of 6-week agomelatine therapy for depressions occurring with different ED variants both in the pattern of the depressive symptom complex and in that of concurrent with and preceding the latter. At the same time, the efficacy of the drug did not depend on the clinical presentations of the leading hypothymic syndrome, the variants of EDs, and the duration of actual depression. However, by the end of the study period, a larger effect was achieved in the therapy for depressions with the hyperphagic variant of EDs, as well as in patients with EDs manifesting in the pattern of depressive symptom complex. Agomelatine has a favorable tolerance profile. BMI tends to become normal in patients with different variants of EDs during the therapy. The adverse events are transient and/or unclear; they do not require therapy discontinuation.Conclusion. Agomelatine is an effective and relatively safe drug that can be recommended to treat depressions concurrent with EDs in therapeutic dosages for at least 6 weeks.

show abstract

unclassified

Depressions with eating disorders: clinical manifestations and therapy

Medvedev

Фролова

Gushanskaya

et al. 2020

RJTAO

Self Cite

View full text Add to dashboard Cite

show abstract

Research Progress on the Treatment of Cognitive Deficits in Patients with Depression

庞¹

2022

ACM

View full text Add to dashboard Cite

Antidepressant therapy in patients with cardiovascular diseases

Medvedev

Korovyakova

Фролова

et al. 2019

Nevrologiâ, nejropsihiatriâ, psihosomatika

Self Cite

View full text Add to dashboard Cite

Депрессивные состояния являются наиболее частой формой психической патологии у пациентов общемедицинских амбулаторных и стационарных учреждений (5,9-24,9%), в том числе у страдающих сердечно-сосудистыми заболеваниями (ССЗ) [1-4]. В кардиологической практике частота депрессии достигает 15-38% [5-8]. По данным отечественного исследования психических расстройств в территориальной поликлинике и многопрофильной больнице, депрессивные состояния выявляются у 29% больных кардиологического отделения [9]. Среди факторов риска развития депрессии при ССЗ ведущие позиции занимают клинико-динамические харак-теристики соматического страдания или такие события, как острый инфаркт миокарда, аортокоронарное шунтирование, наличие других сопутствующих инвалидизирующих заболеваний, а также различные «кардиальные» типы личности-тип А, тип D [10-25]. С о ц и а л ь н о е и м е д и ц и н с к о е з н а ч е н и е д е п р е с с и и Депрессия входит в тройку заболеваний-лидеров с максимальными показателями дезадаптации, выраженными в количестве скорректированных по дезадаптации лет (Disability Adjusted Life Years, DALYs) [26-28]. По данным

show abstract

Treatment of depression with cognitive impairment

Cited by 8 publications

References 16 publications

Depressions with eating disorders: clinical manifestations and therapy

Depressions with eating disorders: clinical manifestations and therapy

Research Progress on the Treatment of Cognitive Deficits in Patients with Depression

Antidepressant therapy in patients with cardiovascular diseases

Contact Info

Product

Resources

About